Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Natera Inc (NTRA)

$33.50 0.00 (0.00%)

17:07 EDT NTRA Stock Quote Delayed 15 Minutes

Volume:

Previous Close $33.50

Market Cap 1.83B

PE Ratio -13.19

EPS -2.54

Volume (Avg. Vol.)

Day's Range 33.50 - 33.50

52-Week Range 11.08 - 34.53

Dividend & Yield N/A (N/A)

NTRA Stock Predictions, Articles, and Natera Inc News

From InvestorPlace
From the Web

3 Stocks to Watch on Wednesday: Caleres Inc (CAL), Everi Holdings Inc (EVRI) and Natera Inc (NTRA)

By Karl Utermohlen, InvestorPlace Writer Mar 14, 2018

Caleres (CAL), Everi Holdings (EVRI) and Natera (NTRA) all reported on their quarterly earnings results after the bell. Here's what you should know.

The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

From Benzinga Sep 17, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals...

Stocks That Hit 52-Week Highs On Monday

From Benzinga Sep 16, 2019

Before 10 am on Monday, 70 stocks hit new 52-week highs. Points of Interest: The largest company by market cap to set a new 52-week high was Zurich Insurance Group (OTC: ZFSVF)....

CBR to Acquire Natera’s Evercord(TM) Cord Blood Business

From MarketJar Sep 13, 2019

This Post Was Syndicated Under License Via QuoteMedia Sharpens Natera's Focus on Reproductive Health, Oncology and Organ Transplant SAN CARLOS, Calif., Sept. 13, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) and CBR (Cord Blood Registry) today announced the acquisition

Natera sells cord blood and tissue banking business

From Seeking Alpha Sep 13, 2019

Natera (NTRA +0.2%) has agreed to sell its Evercord cord blood and tissue banking business to California Life Sciences unit CBR for an undisclosed sum.The company says the divestiture will allow it to

Canaccord Genuity Maintains a Buy Rating on Natera (NTRA)

From Analyst Ratings Sep 12, 2019

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Natera (NTRA – Research Report) yesterday and set a price target of $38. The company’s shares closed last Monday at $30.55, close to its 52-week high of $33.55. Massaro commented: “We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended

Stocks That Hit 52-Week Highs On Friday

From Benzinga Sep 6, 2019

Before 10 am on Friday, 146 companies hit new 52-week highs. Intriguing Points: The largest company by market cap to set a new 52-week high was Nestle (OTC: NSRGY). Channel Hldgs...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!